After receiving his PhD from the Wharton School of the University of Pennsylvania, Donald Kalff spent most of his professional life as a manager at Royal Dutch Shell and as a member of the Executive Board of KLM, Royal Dutch Airlines.
During the last 15 years, he co-founded AIMM Therapeutics, a biotech company that generates antibodies against infectious diseases and cancer with unique proprietary technologies and he also founded MondialDx, a company which markets and develops diagnostic tests for tropical diseases. Moreover, he participates in two companies that develop more effective formulas for medicines for skin diseases and women’s health in the tropics. He has also invested in two companies in the field of cyber security.
Donald Kalff is the author of two books and numerous articles on the governance and management of large enterprises and on the competitiveness of Europe. His latest book, “The European Enterprise, value creation for society” will appear in 2018.
He is a member of the board of the Dutch chapter of Transparency International, the largest anti-corruption network in the world.